You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the clinical trial design of the Reyvow® (lasmiditan) CENTURION study
CENTURION was a phase 3 double-blind, placebo-controlled study that evaluated the first attack efficacy, consistency of response, and safety of Reyvow® (lasmiditan) in the acute treatment of 4 migraine attacks with or without aura.
Date of Last Review: September 13, 2023
Document Number: VV-MED-144872